Skip to content
value.today

CareDx, Inc: peers

Change the peers

CareDx, Inc beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Vitaspring Biomedical Co. Ltd.: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

CareDx, Inc, Celcuity Inc., Vitaspring Biomedical Co. Ltd., Neogen Corporation, BillionToOne, Inc., NeoGenomics, Inc., Sotera Health Company, Grail, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCareDx, Incbase
CDNA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Celcuity Inc.
CELC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Vitaspring Biomedical Co. Ltd.
VSBC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Neogen Corporation
NEOG · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
BillionToOne, Inc.
BLLN · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
NeoGenomics, Inc.
NEO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Sotera Health Company
SHC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Grail, Inc.
GRAL · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$3.4 BOct 19, 2026 · Market data5th of 8$3.5 BOct 5, 2026 · Market data4th of 8$3.1 Blast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8$2.6 BOct 23, 2026 · Market data7th of 8$5.1 BOct 1, 2026 · Market data3rd of 8$2.2 BOct 15, 2026 · Market data8th of 8$5.2 BSep 24, 2026 · Market data2nd of 8$5.3 BOct 19, 2026 · Market data1st of 8$3.5 B8 ranked
Revenue (Better neither way: ranked highest first)$380 MFY2025 · SEC4th of 6————$870 MFY2025 · SEC2nd of 6$305 MFY2025 · SEC5th of 6$727 MFY2025 · SEC3rd of 6$1.2 BFY2025 · SEC1st of 6$147 MFY2025 · SEC6th of 6$554 M6 ranked
Net income (Higher is better)$-21 MFY2025 · SEC5th of 8$-177 MFY2025 · SEC7th of 8$-0 MFY2025 · SEC3rd of 8$-8 MFY2025 · SEC4th of 8$7 MFY2025 · SEC2nd of 8$-108 MFY2025 · SEC6th of 8$78 MFY2025 · SEC1st of 8$-408 MFY2025 · SEC8th of 8$-15 M8 ranked
Employees (Better neither way: ranked highest first)645As on 2021 · Profile5th of 7155December 31, 2025 · Profile7th of 7——2,640As on 2023 · Profile2nd of 7713December 31, 2025 · Profile4th of 72,000As on 2021 · Profile3rd of 73,000As on 2022 · Profile1st of 7490As on 2020 · Profile6th of 77137 ranked
Growth
Market cap change, 30 days (Higher is better)+4.3%30 days to Oct 19, 2026 · Market data1st of 2————-12.9%30 days to Oct 23, 2026 · Market data2nd of 2————————-4.3%2 ranked
Revenue growth (Higher is better)+13.8%FY2025 · SEC3rd of 657th69th————————-2.7%FY2025 · SEC6th of 621st22nd+100.0%FY2025 · SEC1st of 691st96th+10.1%FY2025 · SEC4th of 650th62nd+5.7%FY2025 · SEC5th of 639th48th+17.2%FY2025 · SEC2nd of 663rd75th+11.9%6 ranked
Revenue growth, 3 years a year (Higher is better)+5.7%FY2025 · SEC3rd of 544th55th————————+1.9%FY2025 · SEC5th of 532nd40th————+12.6%FY2025 · SEC2nd of 559th75th+5.0%FY2025 · SEC4th of 542nd53rd+38.4%FY2025 · SEC1st of 585th94th+5.7%5 ranked
Earnings per share growth (Higher is better)————————————————————————+68.8%FY2025 · SEConly one with it83rd85th————+68.8%—
Margins and returns
Gross margin (Higher is better)————————————46.9%FY2025 · SEC3rd of 433rd60th68.3%FY2025 · SEC1st of 465th81st43.2%FY2025 · SEC4th of 427th55th55.5%FY2025 · SEC2nd of 445th69th————51.2%4 ranked
Operating margin (Higher is better)-8.1%FY2025 · SEC3rd of 550th29th————————-2.5%FY2025 · SEC2nd of 554th36th5.3%FY2025 · SEC1st of 565th56th-15.9%FY2025 · SEC4th of 543rd23rd————-382.0%FY2025 · SEC5th of 58th3rd-8.1%5 ranked
Net margin (Higher is better)-5.6%FY2025 · SEC4th of 653rd32nd————————-0.9%FY2025 · SEC3rd of 658th40th2.4%FY2025 · SEC2nd of 665th52nd-14.8%FY2025 · SEC5th of 645th24th6.7%FY2025 · SEC1st of 673rd66th-277.5%FY2025 · SEC6th of 612th4th-3.3%6 ranked
Free cash flow margin (Higher is better)————————————3.7%FY2025 · SEC3rd of 560th48th5.2%FY2025 · SEC2nd of 563rd54th-3.0%FY2025 · SEC4th of 548th28th12.8%FY2025 · SEC1st of 577th76th-203.8%FY2025 · SEC5th of 515th5th3.7%5 ranked
Return on equity (Higher is better)-6.3%FY2025 · SEC4th of 769th36th-163.8%FY2025 · SEC7th of 714th6th————-0.4%FY2025 · SEC3rd of 772nd41st6.5%FY2025 · SEC2nd of 777th54th-12.4%FY2025 · SEC5th of 765th32nd15.4%FY2025 · SEC1st of 787th79th-16.1%FY2025 · SEC6th of 762nd30th-6.3%7 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)26.1×price Oct 19, 2026 · Market data3rd of 344th66th————————————103.0×price Oct 1, 2026 · Market data1st of 389th95th————30.1×price Sep 24, 2026 · Market data2nd of 350th71st————30.1×3 ranked
Price to sales (Better neither way: ranked highest first)6.8×price Oct 19, 2026 · Market data3rd of 664th83rd————————3.0×price Oct 23, 2026 · Market data5th of 643rd60th11.6×price Oct 1, 2026 · Market data2nd of 676th91st2.8×price Oct 15, 2026 · Market data6th of 641st58th4.3×price Sep 24, 2026 · Market data4th of 653rd72nd31.8×price Oct 19, 2026 · Market data1st of 688th96th5.5×6 ranked
Price to book (Better neither way: ranked highest first)11.1×price Oct 19, 2026 · Market data2nd of 786th91st35.2×price Oct 5, 2026 · Market data1st of 796th98th————1.3×price Oct 23, 2026 · Market data7th of 724th29th10.6×price Oct 1, 2026 · Market data3rd of 784th90th2.6×price Oct 15, 2026 · Market data5th of 744th57th8.6×price Sep 24, 2026 · Market data4th of 781st87th2.0×price Oct 19, 2026 · Market data6th of 738th49th8.6×7 ranked
Free cash flow yield (Higher is better)-0.2%price Oct 19, 2026 · Market data4th of 767th36th-4.3%price Oct 5, 2026 · Market data6th of 756th28th————1.2%price Oct 23, 2026 · Market data2nd of 773rd42nd0.3%price Oct 1, 2026 · Market data3rd of 769th38th-1.0%price Oct 15, 2026 · Market data5th of 765th34th2.9%price Sep 24, 2026 · Market data1st of 778th52nd-5.7%price Oct 19, 2026 · Market data7th of 752nd26th-0.2%7 ranked
Financial strength
Debt to equity (Lower is better)————1.4×FY2025 · SEC4th of 583rd77th————0.4×FY2025 · SEC2nd of 546th36th0.1×FY2025 · SEC1st of 523rd16th0.4×FY2025 · SEC3rd of 548th38th3.5×FY2025 · SEC5th of 593rd92nd————0.4×5 ranked
Net debt to EBITDA (Lower is better)————————————6.4×FY2025 · SEC2nd of 290th89th-19.1×FY2025 · SEC1st of 21st0th————————————-6.4×2 ranked
Interest cover (Higher is better)————-12.0×FY2025 · SEC2nd of 240th20th————-0.9×FY2025 · SEC1st of 267th43rd————————————————-6.4×2 ranked
Piotroski F-score (Higher is better)——————6 of 9FY2025 · SEC2nd of 47 of 9FY2025 · SEC1st of 44 of 9FY2025 · SEC4th of 46 of 9FY2025 · SEC2nd of 4——6.0 of 94 ranked
Scorecard
Scorecard (Higher is better)9 of 21FY2025 · Scorecard4th of 82 of 15FY2025 · Scorecard8th of 81 of 7FY2025 · Scorecard7th of 86 of 23FY2025 · Scorecard6th of 88 of 17FY2025 · Scorecard3rd of 811 of 20FY2025 · Scorecard2nd of 812 of 18FY2025 · Scorecard1st of 87 of 17FY2025 · Scorecard5th of 842% passed8 ranked
Valuation checks (Higher is better)1 of 5FY2025 · Scorecard4th of 70 of 4FY2025 · Scorecard6th of 7——2 of 5FY2025 · Scorecard1st of 70 of 5FY2025 · Scorecard6th of 72 of 5FY2025 · Scorecard1st of 72 of 5FY2025 · Scorecard1st of 71 of 5FY2025 · Scorecard4th of 720% passed7 ranked
Growth checks (Higher is better)4 of 6FY2025 · Scorecard5th of 80 of 2FY2025 · Scorecard6th of 80 of 2FY2025 · Scorecard6th of 80 of 6FY2025 · Scorecard6th of 82 of 2FY2025 · Scorecard1st of 84 of 5FY2025 · Scorecard3rd of 86 of 6FY2025 · Scorecard1st of 83 of 4FY2025 · Scorecard4th of 871% passed8 ranked
Profitability checks (Higher is better)1 of 5FY2025 · Scorecard4th of 80 of 3FY2025 · Scorecard6th of 80 of 2FY2025 · Scorecard6th of 80 of 5FY2025 · Scorecard6th of 82 of 3FY2025 · Scorecard1st of 81 of 5FY2025 · Scorecard4th of 82 of 3FY2025 · Scorecard1st of 81 of 4FY2025 · Scorecard3rd of 820% passed8 ranked
Financial health checks (Higher is better)2 of 3FY2025 · Scorecard3rd of 82 of 5FY2025 · Scorecard6th of 80 of 2FY2025 · Scorecard8th of 83 of 6FY2025 · Scorecard5th of 84 of 5FY2025 · Scorecard1st of 83 of 4FY2025 · Scorecard2nd of 81 of 3FY2025 · Scorecard7th of 82 of 3FY2025 · Scorecard3rd of 858% passed8 ranked
Shareholder returns checks (Higher is better)1 of 2FY2025 · Scorecard5th of 80 of 1FY2025 · Scorecard6th of 81 of 1FY2025 · Scorecard1st of 81 of 1FY2025 · Scorecard1st of 80 of 2FY2025 · Scorecard6th of 81 of 1FY2025 · Scorecard1st of 81 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard6th of 875% passed8 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)99.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7117.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7——105.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 738.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7110.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 798.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 784.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 799.0%7 ranked
Institutions holding (Better neither way: ranked highest first)3082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 72692026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7——3382026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 71722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 72972026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 73482026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 74472026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 73087 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+1.5 pp2026-Q2 against 2026-Q1 · 13F6th of 6+14.9 pp2026-Q2 against 2026-Q1 · 13F1st of 6——+1.9 pp2026-Q2 against 2026-Q1 · 13F5th of 6——+9.8 pp2026-Q2 against 2026-Q1 · 13F2nd of 6+6.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 6+1.9 pp2026-Q2 against 2026-Q1 · 13F4th of 6+4.3 pp6 ranked
Dividends
Shareholder yield (Higher is better)2.6%FY2025 · SEC1st of 255th43rd————————————0.0%FY2025 · SEC2nd of 27th3rd————————————1.3%2 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = CareDx, Inc: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Celcuity Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Vitaspring Biomedical Co. Ltd.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Neogen Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BillionToOne, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NeoGenomics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Sotera Health Company: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Grail, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
CareDx, Inc-8.1%FY2025
50th percentile in Healthcaremedian -7.7%, 674 companies
29th percentile in USAmedian 3.5%, 2,594 companies
Celcuity Inc.———
Vitaspring Biomedical Co. Ltd.———
Neogen Corporation-2.5%FY2025
54th percentile in Healthcaremedian -7.7%, 674 companies
36th percentile in USAmedian 3.5%, 2,594 companies
BillionToOne, Inc.5.3%FY2025
65th percentile in Healthcaremedian -7.7%, 674 companies
56th percentile in USAmedian 3.5%, 2,594 companies
NeoGenomics, Inc.-15.9%FY2025
43rd percentile in Healthcaremedian -7.7%, 674 companies
23rd percentile in USAmedian 3.5%, 2,594 companies
Sotera Health Company———
Grail, Inc.-382.0%FY2025
8th percentile in Healthcaremedian -7.7%, 674 companies
3rd percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$291 M$582 M$873 M$1.2 B20112013201520172019202120232025CareDx, Inc $380 MVitaspring Biomedical Co. Ltd. $6 MNeogen Corporation $870 MBillionToOne, Inc. $305 MNeoGenomics, Inc. $727 MSotera Health Company $1.2 BGrail, Inc. $147 M

Rank in the group

1st2nd3rd4th5th6th201120122013201420152016201720182019202020212022202320242025CareDx, Inc: 3rd of 3 in 2012CareDx, Inc: 3rd of 3 in 2013CareDx, Inc: 3rd of 3 in 2014CareDx, Inc: 3rd of 3 in 2015CareDx, Inc: 3rd of 3 in 2016CareDx, Inc: 3rd of 4 in 2017CareDx, Inc: 3rd of 4 in 2018CareDx, Inc: 4th of 5 in 2019CareDx, Inc: 4th of 5 in 2020CareDx, Inc: 4th of 5 in 2021CareDx, Inc: 4th of 5 in 2022CareDx, Inc: 4th of 6 in 2023CareDx, Inc: 4th of 6 in 2024CareDx, Inc: 4th of 6 in 2025CareDx, IncVitaspring Biomedical Co. Ltd.: 4th of 4 in 2017Vitaspring Biomedical Co. Ltd.: 4th of 4 in 2018Vitaspring Biomedical Co. Ltd.: 5th of 5 in 2019Vitaspring Biomedical Co. Ltd.: 5th of 5 in 2020Vitaspring Biomedical Co. Ltd.: 5th of 5 in 2021Vitaspring Biomedical Co. Neogen Corporation: 1st of 2 in 2011Neogen Corporation: 1st of 3 in 2012Neogen Corporation: 1st of 3 in 2013Neogen Corporation: 1st of 3 in 2014Neogen Corporation: 1st of 3 in 2015Neogen Corporation: 1st of 3 in 2016Neogen Corporation: 1st of 4 in 2017Neogen Corporation: 1st of 4 in 2018Neogen Corporation: 2nd of 5 in 2019Neogen Corporation: 2nd of 5 in 2020Neogen Corporation: 2nd of 5 in 2021Neogen Corporation: 2nd of 5 in 2022Neogen Corporation: 2nd of 6 in 2023Neogen Corporation: 2nd of 6 in 2024Neogen Corporation: 2nd of 6 in 2025Neogen CorporationBillionToOne, Inc.: 6th of 6 in 2023BillionToOne, Inc.: 5th of 6 in 2024BillionToOne, Inc.: 5th of 6 in 2025BillionToOne, Inc.NeoGenomics, Inc.: 2nd of 2 in 2011NeoGenomics, Inc.: 2nd of 3 in 2012NeoGenomics, Inc.: 2nd of 3 in 2013NeoGenomics, Inc.: 2nd of 3 in 2014NeoGenomics, Inc.: 2nd of 3 in 2015NeoGenomics, Inc.: 2nd of 3 in 2016NeoGenomics, Inc.: 2nd of 4 in 2017NeoGenomics, Inc.: 2nd of 4 in 2018NeoGenomics, Inc.: 3rd of 5 in 2019NeoGenomics, Inc.: 3rd of 5 in 2020NeoGenomics, Inc.: 3rd of 5 in 2021NeoGenomics, Inc.: 3rd of 5 in 2022NeoGenomics, Inc.: 3rd of 6 in 2023NeoGenomics, Inc.: 3rd of 6 in 2024NeoGenomics, Inc.: 3rd of 6 in 2025NeoGenomics, Inc.Sotera Health Company: 1st of 5 in 2019Sotera Health Company: 1st of 5 in 2020Sotera Health Company: 1st of 5 in 2021Sotera Health Company: 1st of 5 in 2022Sotera Health Company: 1st of 6 in 2023Sotera Health Company: 1st of 6 in 2024Sotera Health Company: 1st of 6 in 2025Sotera Health CompanyGrail, Inc.: 5th of 5 in 2022Grail, Inc.: 5th of 6 in 2023Grail, Inc.: 6th of 6 in 2024Grail, Inc.: 6th of 6 in 2025Grail, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCareDx, IncCelcuity Inc.Vitaspring Biomedical Co. Ltd.Neogen CorporationBillionToOne, Inc.NeoGenomics, Inc.Sotera Health CompanyGrail, Inc.
2025$380 MSEC4th——$870 MSEC2nd$305 MSEC5th$727 MSEC3rd$1.2 BSEC1st$147 MSEC6th
2024$334 MSEC4th——$895 MSEC2nd$153 MSEC5th$661 MSEC3rd$1.1 BSEC1st$126 MSEC6th
2023$280 MSEC4th——$924 MSEC2nd$72 MSEC6th$592 MSEC3rd$1.0 BSEC1st$93 MSEC5th
2022$322 MSEC4th——$822 MSEC2nd—$510 MSEC3rd$1.0 BSEC1st$56 MSEC5th
2021$296 MSEC4th—$6 MSEC5th$527 MSEC2nd—$484 MSEC3rd$931 MSEC1st—
2020$192 MSEC4th—$0 MSEC5th$468 MSEC2nd—$444 MSEC3rd$818 MSEC1st—
2019$127 MSEC4th—$0 MSEC5th$418 MSEC2nd—$409 MSEC3rd$778 MSEC1st—
2018$77 MSEC3rd—$0 MSEC4th$414 MSEC1st—$277 MSEC2nd——
2017$48 MSEC3rd—$0 MSEC4th$398 MSEC1st—$240 MSEC2nd——
2016$41 MSEC3rd——$358 MSEC1st—$232 MSEC2nd——
2015$28 MSEC3rd——$321 MSEC1st—$100 MSEC2nd——
2014$27 MSEC3rd——$283 MSEC1st—$87 MSEC2nd——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of CareDx, Inc#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Celcuity Inc.CELC · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $3.5 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $3.5 B (Oct 5, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Vitaspring Biomedical Co. Ltd.VSBC · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $3.1 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $3.1 B (last known, Jan 5, 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Neogen CorporationNEOG · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $2.6 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2.6 B (Oct 23, 2026) · revenue $870 M (year to May 2026)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • BillionToOne, Inc.BLLN · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $5.1 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.1 B (Oct 1, 2026) · revenue $305 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • NeoGenomics, Inc.NEO · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $2.2 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2.2 B (Oct 15, 2026) · revenue $727 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Sotera Health CompanySHC · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $5.2 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.2 B (Sep 24, 2026) · revenue $1.2 B (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Grail, Inc.GRAL · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $5.3 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.3 B (Oct 19, 2026) · revenue $147 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • RadNet, Inc.RDNT · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $5.8 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $5.8 B (Oct 28, 2026) · revenue $2.0 B (year to December 2025)
    96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Fortrea Holdings Inc.FTRE · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $2.0 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2.0 B (Oct 9, 2026) · revenue $2.7 B (year to December 2025)
    96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    + Add
  • Caris Life Sciences, Inc.CAI · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $6.2 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $6.2 B (Aug 1, 2026) · revenue $812 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    + Add
  • Lantheus Holdings, Inc.LNTH · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $6.5 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $6.5 B (Oct 26, 2026) · revenue $1.5 B (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    + Add
  • Freenome, Inc.FRNM · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $1.7 B market cap against $3.4 B · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.7 B (Oct 2, 2026)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.